Citations

Clear

3042 citation(s) found for "Kumar, S".

5122 Severe Hypercalcemia as a Manifestation of Immune Reconstitution Inflammatory Syndrome in a Patient with AIDS and Disseminated MAC Infection
Rad, Mona Vahidi, Ahmed, Samir, Kumar, Aditi

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.497 Get It

Abstract Disclosure: M. Vahidi Rad: None. S. Ahmed: None. A. Kumar: None. Introduction: Granulomatous disease can cause hypercalcemia due to increased production of 1,25 dihydroxyvitamin-D. Mycobacterium avium complex (MAC) infection is an AIDS (acquired immunodeficiency syndrome)-defining illness and a granulomatous disease that can lead to hypercalcemia. We report a case of severe hypercalcemia from Immune Reconstitution Inflammatory Syndrome (IRIS) in a patient with AIDS and disseminated MAC which developed several months after initiation of appropriate antibiotic and antiviral therapy. Clinical Case: A 30-year-old female with HIV on anti-retroviral therapy and disseminated MAC infection on antibiotics developed PTH independent mild hypercalcemia in the 10.9-11.5 mg/dL range about 4 months after initiation of antiviral and antibiotic therapy. 1,25 dihydroxyvitamin D level was normal at 50 pg/mL (reference range 18-78 pg/mL). The hypercalcemia worsened and about 8 months after initiation of antimicrobial therapy, she had a hospitalization for severe hypercalcemia with corrected calcium of 15.2 mg/dL and acute kidney injury. PTH was suppressed at 6.9 pg/mL and repeat 1,25 dihydroxyvitamin D level was elevated at 129 pg/mL (reference range 18-78 pg/mL). Other testing for PTH independent hypercalcemia including PTH- Related Peptide, serum protein electrophoresis (SPEP) and TSH were normal. She was diagnosed with hypercalcemia from increased calcitriol production in the setting of IRIS secondary to disseminated MAC. Hypercalcemia secondary to increased production of calcitriol in patients with MAC and HIV infection might happen or worsen months after starting the antimicrobial treatments and has been reported as a potential manifestation of immune reconstitution. MAC-associated IRIS has been reported to be associated with a T-helper cell response with increased number of interferon-gamma-producing T-cells and Th1-cytokines that can potentially cause a granulomatous reaction. These granulomas will have increased macrophage 1-alpha-hydroxylase activity that can further result in more production of 1,25 dihydroxyvitamin D3 and cause more hypercalcemia. Prednisone was started with resultant improvement in hypercalcemia. Conclusion: Severe hypercalcemia due to worsening of subclinical granulomatous infections such as MAC can be a manifestation of IRIS in patients with HIV infection or AIDS who are on antiretroviral treatments. This responds to glucocorticoids. Presentation: 6/2/2024
Molecular Markers in the World Health Organization Classification of Head and Neck Tumors, Fifth Edition
Agarwal, Amit , Bathla, Girish , Bhatt, Alok A. , Rao, Dinesh , Vijay, Kanupriya , Rhyner, Patricia, Bhatt, Alok A , Murray, John, Vijay, Kanupriya , Vibhute, Prasanna , Bathla, Girish , Agarwal, Amit Kumar , Murray, John Vincent

Mayo Clinic

RadioGraphics | October 2, 2024 | Volume: 44 | Issue: 10 | Pages: No page available

10.1148/rg.240037 | PMID 39356632 Get It

Mohs Micrographic Surgery With Melanocytic Immunostains for T1a/b Invasive Melanoma Yields
Kumar, Anagha , Trischman, Thomas , Asamoah, Eucabeth, Vidal, Nahid Y. , Demer, Addison M. , Todd, Austin W.

Mayo Clinic

Dermatologic Surgery | September 30, 2024 | Volume: 51 | Issue: 2 | Pages: 123-126

10.1097/dss.0000000000004414 | PMID 39347647 Get It

BACKGROUND The use of Mohs micrographic surgery with melanocytic immunostains (MMS-I) for cutaneous melanoma is increasing. OBJECTIVE To assess local recurrence, melanoma-specific death rates in patients with invasive melanoma treated with MMS-I. MATERIALS AND METHODS A single-center retrospective review of patients with invasive melanoma treated with MMS-I from January 2008 to December 2018. RESULTS Three hundred fifty-two patients (359 melanomas) were included. The median age was 71 years; most patients were male (252%; 71.6%). Most tumors were T1a/b (341, 95%), H/N (322; 89.7%), and lentigo maligna subtype (281, 78.3%). At a median follow-up of 4.3 years, local recurrence rates were 1.4% (5) and 0.9% (3) among all-stage and T1a/b tumors, respectively. There were 3 melanoma-related deaths (0.9%). CONCLUSION MMS-I is associated with <1% risk of local recurrence and disease-specific mortality for T1a/b melanomas.
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
Fornaro, Marco , Venerito, Vincenzo , Pellico, Maria Rosa , Iannone, Florenzo , Joshi, Mrudula , Chen, Yi‐Ming , Tan, Ai Lyn , Saha, Sreoshy , Chatterjee, Tulika , Agarwal, Vishwesh , Kadam, Esha , Hasan, A T M Tanveer , Shumnalieva, Russka , Milchert, Marcin , Tan, Chou Luan , Vaidya, Binit , Kuwana, Masataka , Shaharir, Syahrul Sazliyana , Tehozol, Erick Adrian Zamora , Gutiérrez, Carlos Enrique Toro , Goo, Phonpen Akawatcharangura , Katchamart, Wanruchada , Parodis, Ioannis , Nikiphorou, Elena , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, CoVAD Study, Sen, Parikshit, Javaid, Mahnoor, Andreoli, Laura, Lini, Daniele, Schreiber, Karen, Nune, Arvind, Tan, Ai Lyn, Patel, Aarat, Pauling, John D, Wincup, Chris, Barman, Bhupen, Torre, Ignacio García-De La, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Kibbi, Lina El, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Griger, Zoltán, Kardes, Sinan, Vince, Melinda Nagy, Singh, Yogesh Preet, Ranjan, Rajiv, Jain, Avinash, Pandya, Sapan C, Pilania, Rakesh Kumar, Sharma, Aman, M, Manesh Manoj, Gupta, Vikas, Kavadichanda, Chengappa G, Patro, Pradeepta Sekhar, Ajmani, Sajal, Phatak, Sanat, Goswami, Rudra Prosad, Chowdhury, Abhra Chandra, Mathew, Ashish Jacob, Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj, Pande, Arunkumar R, Chandwar, Kunal, Ghodke, Akanksha, Boro, Hiya, Fazal, Zoha Zahid, Vaidya, Binit, Cansu, Döndü Üsküdar, Yıldırım, Reşit, Gasparyan, Armen Yuri, Papa, Nicoletta Del, Sambataro, Gianluca, Fabiola, Atzeni, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Angelis, Rossella De, Danieli, Maria Giovanna, Grignaschi, Silvia, Giollo, Alessandro, Alunno, Alessia, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, Loarce-Martos, Jesús, Prieto-González, Sergio, Gonzalez, Raquel Aranega, Yoshida, Akira, Nakashima, Ran, Sato, Shinji, Kimura, Naoki, Kaneko, Yuko, Gono, Takahisa, Tomaras, Stylianos, Proft, Fabian Nikolai, Holzer, Marie-Therese, Gromova, Margarita Aleksandrovna, Aharonov, Or, Griger, Zoltán, Hmamouchi, Ihsane, bouchti, Imane El, Baba, Zineb, Giannini, Margherita, Maurier, François, Campagne, Julien, Meyer, Alain, Langguth, Daman, Limaye, Vidya, Needham, Merrilee, Srivastav, Nilesh, Hudson, Marie, Landon-Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Arbeláez, Álvaro, Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico, Zimba, Olena, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Airenakho, Emorinken, Madu, Nwankwo Henry, Yerima, Abubakar, Olaosebikan, Hakeem, Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Ugarte-Gil, Manuel Francisco, Chinchay, Lyn, Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A, Harifi, Ghita, Fuentes-Silva, Yurilís, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio, Bautista, Generoso Guerra, Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, M, Cristian Vergara, Báez, Jossiell Then, Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Salinas, Rodrigo García, Obiols, Alejandro Quiñónez, Chávez, Nilmo, Ordóñez, Andrea Bran, Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina, Hidalgo, Eduardo Romero, Saenz, Ricardo, M, Idania Escalante, Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Pauling, John D , Wincup, Chris , Sambataro, Gianluca , Angelis, Rossella De , Loarce‐Martos, Jesus , Lini, Daniele , Fuentes-Silva, Yurilís , Giollo, Alessandro , Grignaschi, Silvia , Schreiber, Karen , Danieli, Maria Giovanna , Gupta, Latika , Shinjo, Samuel Katsuyuki , Hoff, Leonardo Santos , Kadam, Esha , Ziade, Nelly , Velikova, Tsvetelina , Hasan, A T M Tanveer , Shumnalieva, Russka , Milchert, Marcin , Tan, Chou Luan , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Vaidya, Binit , Kuwana, Masataka , Sazliyana Shaharir, Syahrul , Knitza, Johannes , Makol, Ashima , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , Halabi, Hussein , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Distler, Oliver , Katchamart, Wanruchada , Day, Jessica , Parodis, Ioannis , Nikiphorou, Elena , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika , Joshi, Mrudula , Agarwal, Vishwesh , Tan, Ai Lyn , Chatterjee, Tulika , Pauling, John D , Wincup, Chris , Chen, Yi-Ming , Saha, Sreoshy , De Angelis, Rossella , Iannone, Florenzo , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Makol, Ashima , Halabi, Hussein , Dey, Dzifa , Caballero‐Uribe, Carlo V. , Distler, Oliver , Day, Jessica , Group, CoVAD Study, Sen, Parikshit, Javaid, Mahnoor, Andreoli, Laura, Nune, Arvind, Tan, Ai Lyn, Patel, Aarat, Barman, Bhupen, Torre, Ignacio García-De La, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Kibbi, Lina El, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Griger, Zoltán, Kardes, Sinan, Vince, Melinda Nagy, Singh, Yogesh Preet, Ranjan, Rajiv, Jain, Avinash, Pandya, Sapan C, Pilania, Rakesh Kumar, Sharma, Aman, M, Manesh Manoj, Gupta, Vikas, Kavadichanda, Chengappa G, Patro, Pradeepta Sekhar, Ajmani, Sajal, Phatak, Sanat, Goswami, Rudra Prosad, Chowdhury, Abhra Chandra, Mathew, Ashish Jacob, Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj, Pande, Arunkumar R, Chandwar, Kunal, Ghodke, Akanksha, Boro, Hiya, Fazal, Zoha Zahid, Vaidya, Binit, Cansu, Döndü Üsküdar, Yıldırım, Reşit, Gasparyan, Armen Yuri, Papa, Nicoletta Del, Fabiola, Atzeni, Govoni, Marcello, Parisi, Simone, Bocci, Elena Bartoloni, Sebastiani, Gian Domenico, Fusaro, Enrico, Sebastiani, Marco, Quartuccio, Luca, Franceschini, Franco, Sainaghi, Pier Paolo, Orsolini, Giovanni, Alunno, Alessia, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, Prieto-González, Sergio, Gonzalez, Raquel Aranega, Yoshida, Akira, Nakashima, Ran, Sato, Shinji, Kimura, Naoki, Kaneko, Yuko, Gono, Takahisa, Tomaras, Stylianos, Proft, Fabian Nikolai, Holzer, Marie-Therese, Gromova, Margarita Aleksandrovna, Aharonov, Or, Griger, Zoltán, Hmamouchi, Ihsane, bouchti, Imane El, Baba, Zineb, Giannini, Margherita, Maurier, F. , Campagne, Julien, Meyer, Alain , Langguth, Daman, Limaye, Vidya, Needham, Merrilee, Srivastav, Nilesh, Hudson, Marie, Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Arbeláez, Álvaro, Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico, Zimba, Olena, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Airenakho, Emorinken, Madu, Nwankwo Henry, Yerima, Abubakar, Olaosebikan, Hakeem, Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Ugarte-Gil, Manuel Francisco, Chinchay, Lyn, Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio, Bautista, Generoso Guerra, Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, M, Cristian Vergara, Báez, Jossiell Then, Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Salinas, Rodrigo García, Obiols, Alejandro Quiñónez, Chávez, Nilmo, Ordóñez, Andrea Bran, Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina, Hidalgo, Eduardo Romero, Saenz, Ricardo, M, Idania Escalante, Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela

Mayo Clinic

Rheumatology | September 26, 2024 | Volume: 64 | Issue: 4 | Pages: 2133-2142

10.1093/rheumatology/keae520 | PMID 39324556 Get It

Abstract Objective The presence of comorbidities can substantially affect patients’ quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited. Methods We examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs) and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined basic multimorbidity (BM) as the presence of ≥2 non-rheumatic chronic conditions and complex multimorbidity (CM) as the presence of ≥3 non-rheumatic chronic conditions affecting ≥3 organ systems. Hierarchical clustering on principal components was performed for grouping. Results Among the COVAD respondents, 1558 IIMs, 4591 oAIRDs and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (odds ratio [OR]: 1.62 vs oAIRDs and 2.95 vs HCs, P &lt; 0.01), BM (OR: 1.66 vs oAIRDs and 3.52 vs HCs, P &lt; 0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, P &lt; 0.01) and mental health disorders (MHDs) (OR: 1.33 vs oAIRDs and 2.63 vs HCs, P &lt; 0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all P &lt; 0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores. Conclusion Patients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Banerjee, Rahul , Sexton, Rachael, Cowan, Andrew J., Rosenberg, Aaron S. , Kumar, Shaji , Durie, B G M, Richardson, Paul G. , Hoering, Antje , Orlowski, Robert Z. , Kumar, Shaji K , Dispenzieri, Angela , Orlowski, Robert Z. , Banerjee, Rahul , Rosenberg, Aaron , Ailawadhi, Sikander , Rajkumar, S. Vincent , Dispenzieri, Angela , Lonial, Sagar , Richardson, Paul Gerard Guy , Usmani, Saad Z.

Mayo Clinic

Blood | September 25, 2024 | Volume: 145 | Issue: 1 | Pages: 75-84

10.1182/blood.2024025939 | PMID 39321347 Get It

Abstract Dexamethasone is a key component of induction for newly diagnosed multiple myeloma (NDMM), despite common toxicities, including hyperglycemia and insomnia. In the randomized ECOG E4A03 trial, dexamethasone 40 mg once weekly was associated with lower mortality than higher doses. However, the performance of dexamethasone dose reductions below this threshold with regard to progression-free survival (PFS) and overall survival (OS) in NDMM has not been fully characterized. We conducted a secondary pooled analysis of the SWOG 0777 and SWOG 1211 studies of NDMM, which used lenalidomide and dexamethasone (Rd) alone, with or without bortezomib, and with or without elotuzumab. The planned dexamethasone intensity was 40 to 60 mg weekly in all arms. Patients were categorized into FD-DEX (full-dose dexamethasone maintained throughout induction) or LD-DEX (lowered-dose dexamethasone or discontinuation; only permitted for grade 3+ toxicities per both study protocols). Of the 541 evaluated patients, the LD-DEX group comprised 373 patients (69%). There were no differences in PFS or OS between the FD-DEX and LD-DEX groups, which were balanced in terms of age, stage, and performance status. Predictors of PFS and OS in the multivariate models were treatment arm, age ≥70 years, and thrombocytopenia. FD-DEX did not significantly improve either outcome. Our study suggests that dexamethasone dose reductions are common in multiple myeloma, even within clinical trials. Given the many toxicities and unclear benefits of dexamethasone in the era of modern treatment regimens, dexamethasone dose reduction during NDMM induction warrants further prospective studies. These trials were registered at www.clinicaltrials.gov as #NCT00644228 and NCT01668719.
Abstract C100: Defining the role of Hedgehog, Notch, and Wnt signaling pathways in aggressive lethal prostate cancer of Hispanic men
Recio‐Boiles, Alejandro , Deshmukh, Sachin Kumar , Barker, Kenneth N. , Wu, Sharon , Xiu, Joanne , Radovich, Milan , Heath, Elisabeth I. , McKay, Rana R. , Miranti, Cynthia , Estrada-Mendizábal, Ricardo J. , Chipollini, Juan

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: C100-C100

10.1158/1538-7755.disp24-c100 Get It

Abstract Background: Hispanic American (HA) men with prostate cancer (PC) are more likely to have more aggressive and advanced diseases and greater mortality rates compared to non-Hispanic white (NHW) men. Resistance to the current anticancer therapy is the major hurdle that leads to poor clinical outcomes. Hedgehog, Notch, and Wnt signaling pathways play a crucial role in development, progression, and resistance to the various anticancer therapies. Here, we characterized the enrichment of Hedgehog, Notch, and Wnt signaling pathways and molecular tumors differences between HA and NHW patients. Methods: Our data consist of 88 PC tumors samples (HA=34, NHW=54) obtained from treatment-naive metastatic hormone-sensitive prostate cancer (mHSPC) that were analyzed by next-generation sequencing (592, NextSeq; Whole Exome Sequencing, NovaSeq) and Whole Transcriptome Sequencing (WTS; NovaSeq) (Caris Life Sciences, Phoenix, AZ). Pathway enrichment was determined by Gene Set Enrichment Analysis (GSEA, Broad Institute) by measurable TPM (transcripts per kilobase million). The medical records were reviewed in a deidentified fashion for clinical features. Statistical significance was determined using chi-square and Mann-Whitney U (p&lt;0.05). Results: HA PC had enrichment of Hedgehog signaling (NES: 1.45, FDR=0.04), Notch signaling (NES: 1.41, FDR=0.07), and Wnt/β-catenin signaling (NES: 1.38, FDR=0.11) pathways compared to NHW tumors. HA tumors had higher expression of genes (HES1, Notch1, WNT1, WNT2; FC:1.1-2.5) associated with crosstalk between Hedgehog, Notch, and Wnt/β- catenin signaling pathways (all p&lt;0.05). Moreover, HA tumors had higher expression of stemness (ALDH1A2, ALDH1A1, PROM1; FC: 1.7-3.0), drug efflux (ABCC1, ABCB1; FC: 1.1- 1.5), epithelial to mesenchymal transition (EMT) (TWIST1, MMP2; FC: 1.1-1.5), cell cycle (CCND2; FC: 1.2), inhibition of apoptosis (BIRC2, XIAP; FC: 1.1) and epigenetic (EP300, TET1, TET2; FC: 1.3-1.4) related genes compared to NHW tumors (all p&lt;0.05). HA PC had higher frequency of Hedgehog and Wnt/β-catenin associated SPOP (16% vs 6.6%, p=0.2) and CTNNB1 (12% vs 2.2%, p=0.1) mutation compared to NHW PC. Conclusion: These results demonstrate that tumors from HA patients had enrichment of oncogenic Hedgehog, Notch, and Wnt/β-catenin signaling pathways, higher expression of stemness, drug efflux, EMT, cell cycle, inhibition of apoptosis and epigenetic-related genes, and mutations directly involved in activating the Hedgehog and Wnt/β-catenin signaling pathways. Together, these findings suggest that tumors from HA patients are enriched for gene signatures that promote cancer progression and therapy resistance. Additional research on collaboration and crosstalk between Hedgehog, Notch, and Wnt/β-catenin signaling pathways may help in designing better therapeutic strategies for HA men with mHSPC. Citation Format: Alejandro Recio-Boiles, Sachin Kumar Deshmukh, Ricardo J. Estrada-Mendizabal, Kenneth Barker, Sharon Wu, Joanne Xiu, Milan Radovich, Elisabeth I. Heath, Rana McKay, Juan Chipollini, Cynthia K. Miranti. Defining the role of Hedgehog, Notch, and Wnt signaling pathways in aggressive lethal prostate cancer of Hispanic men [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C100.
The Quality of Life after Endometrial Cancer Study: Baseline Characteristics and Patient-Reported Outcomes
Warring, Simrit K. , Yost, Kathleen J. , Dowdy, S.C., Kumar, Amanika , Lemens, Maureen A. , Oort, Chelsie C. Van, Fought, Angela J. , Gree, Michaela E. Mc, Glaser, Gretchen , Warring, Simrit, Kumar, Amanika , Lemens, Maureen A , Van Oort, Chelsie C, Mc Gree, Michaela E, Glaser, Gretchen , Cheville, Andrea , Faubion, Stephanie S. , Mariani, Andrea

Mayo Clinic

Current Oncology | September 19, 2024 | Volume: 31 | Issue: 9 | Pages: 5557-5572

10.3390/curroncol31090412 | PMID 39330040 Get It

Endometrial cancer (EC) patients make up the second largest group of female cancer survivors. Patient-reported outcomes (PROs) including quality of life (QOL) and sexual function and satisfaction (SF and S) are critical facets of survivorship. This prospective, longitudinal study assesses associations between baseline characteristics and PROs after treatment. Herein, we report the baseline clinical characteristics and PROs prior to treatment initiation. Outcomes post-treatment over time will be reported separately. Patients with planned surgery for EC were prospectively enrolled in 2019–2021 and administered the European Organization for Research and Treatment of Cancer (EORTC) QOL Questionnaire Core 30 (QLQ-C30), EORTC QLQ EC Module (EN24), Patient-Reported Outcomes Measurement Information System (PROMIS), and the Mayo Clinic lower extremity lymphedema (LEL) questionnaire. This study enrolled 198 patients with a mean (SD) age of 63.6 (9.8) years and body mass index of 35.5 (8.3) kg/m2. No significant differences in the PROs for the QOL were seen when compared to the reference means (SD) except for the lower interest in sexual activity (31.9 (9.8) vs. 47.5 (SE0.70)) and lower fatigue (21.3 (19.8) vs. 31.7 (25.9)). Increased obesity was associated with an increased likelihood of LEL (p < 0.01) and multiple QOL scales, including poorer global health status (p < 0.01) and physical functioning (p < 0.01). Prior to treatment initiation for EC, the patients had a similar QOL compared to that of the general population. The patients with increasing obesity, a known risk factor for EC, had worse overall global health status and physical functioning. A better understanding of these QOL measures is imperative for earlier identification and intervention of patients at risk of chronic impairments from EC treatment.
Demographic characteristics and comorbidities of patients with narcolepsy: a propensity-matched cohort study
Ip, Wui , Tippmann‐Peikert, Maja, Asfahan, Shahir , Singh, Gajinder Pal, Gudeman, Jennifer , Lipford, Melissa C. , Moore, J Layne, Tippmann-Peikert, Maja, Awasthi, Samir , Moore, J Layne, Kumar, Praveen M

Mayo Clinic

Sleep Advances | September 14, 2024 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/sleepadvances/zpae067 | PMID 39403405 Get It

Abstract Study Objectives Narcolepsy has a complex phenotype owing to differences in symptomatology, disease severity, and comorbidities. This is the first study to use aggregate electronic health record (EHR) data and natural language processing (NLP) algorithms to characterize the demographics and comorbidities of a large cohort of patients with narcolepsy. Methods First-time Mayo Clinic patients (2000–2020) who had ≥1 narcolepsy-specific ICD-9/10 code and ≥1 disease-supportive statement in the clinical notes (identified using an NLP algorithm) were identified. A control cohort was propensity matched for birth year, age at first institutional encounter, sex, race, ethnicity, number of diagnosis codes, and mortality. Common comorbidities were compared and ranked between cohorts. Results In the EHR database (N = 6 389 186 patients), 2057 patients with narcolepsy were identified (median age, 32 years; 59.6% female; 92.6% white; and 89.2% non-Hispanic) and propensity matched with a control cohort. Among the top 20 comorbidities occurring more frequently in the narcolepsy cohort compared with the control cohort (odds ratio [OR], 1.67–3.94; p &lt; .001]) were sleep disorders (restless legs syndrome, obstructive sleep apnea, and insomnia), mood disorders (depression, dysthymia, and anxiety), and pain disorders (chronic pain syndrome, migraine, fibromyalgia, carpal tunnel syndrome, and myalgia). Other comorbidities significantly associated with narcolepsy (OR, 1.33–1.95) were irritable bowel syndrome (p &lt; .001), asthma (p &lt; .001), cervical spondylosis (p &lt; .01), syncope (p &lt; .01), and hypothyroidism (p &lt; .05). Conclusions This propensity-matched cohort study demonstrates increased psychiatric, sleep, and pain disorders in patients living with narcolepsy and challenges beyond narcolepsy-specific symptoms in this population. Understanding common narcolepsy-associated comorbidities may assist in tailoring treatment modalities.